1. Validation of patient global item for quality of life impact on Hidradenitis suppurativa
- Author
-
Kirby, J .S., Hereford, B., Thorlacius, L., Villumsen, B., Ingram, J. R., Garg, A., Butt, M., Esmann, S., King, T., Tan, J., and Jemec, G. B. E.
- Abstract
Background\ud \ud Hidradenitis suppurativa (HS) is a chronic inflammatory disease that is not well understood. The HS core outcome set calls for a patient global assessment (PtGA), for which measures are limited.\ud Objectives\ud \ud Our aim is to assess the validity, reliability, and responsiveness of a candidate single‐item PtGA for HS‐specific health‐related quality of life (HRQOL).\ud Methods\ud \ud Cognitive debriefing interviews were conducted with HS patients in Denmark (DK) and the United States (US). Field testing was conducted via a cross‐sectional observational study with adults with HS in the US and DK. The candidate PtGA item, demographic items, and multiple patient‐reported scales including the Hidradenitis Suppurativa Quality of Life (HiSQOL), Dermatology Life Quality Index (DLQI), numerical rating scale (NRS) for pain were concurrently administered to evaluate convergent and known‐groups validity. The scales with a single‐item assessment of change were administered again 24‐72 hours later to evaluate reliability and responsiveness.\ud Results\ud \ud After cognitive debriefing, the candidate PtGA for HS‐specific HRQOL was finalized with five response levels. Convergent validity of the PtGA was supported with significant correlations with the HiSQOL score r = 0.79 [95CI: 0.75‐0.82] and DLQI (r = 0.78, [95CI: 0.74‐0.82]). The PtGA displayed known‐groups validity with the DLQI score bands based on significance of an analysis of variance (p
- Published
- 2021